Jonathan H Kaufman bought $45k of LIPO
See remarks below. at LIPELLA PHARMACEUTICALS INC.. 55,000 shares at an average of $0.83, traded Mar 18, 2024, filed Mar 19, 2024.
Score components
- +15RoleOfficer
- +6Trade size$45k at market
- +3Relative to holdingsHoldings up 7%
- +8Price context71% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -4.3%, 3m -14.6%, 6m -45.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001753926-24-000573, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 18, 2024 | POpen-market purchase Common Stock | +30,000 | $0.79 | $24k | 863,849 | Mar 19, 2024 |
| Mar 19, 2024 | POpen-market purchase Common Stock | +25,000 | $0.87 | $22k | 888,849 | Mar 19, 2024 |
| Mar 15, 2024 | AGrant or award Stock Optionsderivative | +80,000 | $0.00 | $0 | 80,000 | Mar 19, 2024 |
Related signals
Other insiders at LIPELLA PHARMACEUTICALS INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | LIPObuy LIPELLA PHARMACEUTICALS INC. | Jonathan H Kaufman See remarks below. | $7,590 10,000 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.